Navigation Links
Halozyme Therapeutics to Present at Upcoming Investor Conferences
Date:10/22/2008

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will present at three upcoming investor conferences:

-- BIOCOM Investor Conference to be held at the Hyatt Regency in La Jolla, Calif. on Monday, October 27, 2008 at 2:00 p.m. PDT (5:00 p.m. EDT);

-- Oppenheimer's 19th Annual Healthcare Conference to be held at the Waldorf-Astoria Hotel in New York on Monday, November 3, 2008 at 10:40 a.m. EST (7:40 a.m. PST); and

-- Lazard Capital Markets 5th Annual Healthcare Conference to be held at the St. Regis Hotel in New York on Tuesday, November 18, 2008 at 2:40 p.m. EST (11:40 a.m. PST).

Interested parties can access a live audio webcast and accompanying slides of the conference presentations via the internet by visiting the Investor Relations section of Halozyme's website at http://www.halozyme.com. Archived presentations will be available on the website for 30 days following the presentation dates.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological thera
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Halozyme Therapeutics to Host Research Day for Investors and Analysts
2. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
7. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
8. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
9. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
10. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... YORK , March 27, 2015   ... in liquid photopurification, announced today that the Company ... for the continued trading of SurePure ("SURP") securities ... venture marketplace for entrepreneurial and development stage companies. ... Group introduced standards and eligibility requirements designed to ...
(Date:3/27/2015)... SHANGHAI , March 27, 2015 ... a leading open-access R&D capability and technology platform ... device industries, announced today that an Investigational New ... monoclonal antibody for rheumatoid arthritis has been accepted ... Administration (CFDA).  In September 2012, ...
(Date:3/26/2015)... Bioscience, Inc. (NASDAQ: ROKA ), a molecular ... for the detection of foodborne pathogens, today reported ... full year ended December 31, 2014. ... ended December 31, 2014 was $1.4 million compared ... and $1.5 million for the third quarter of ...
(Date:3/26/2015)... CO (PRWEB) March 26, 2015 The ... has formed a strategic alliance with Designing Gig LLC ... their clients. , “Forging this alliance with ... Now we can extend a comprehensive, end-to-end, digital ... development, strategy, and execution,” said Chuck Miller, president of ...
Breaking Biology Technology:SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2
... Bulletin Board: DSCI), a provider of advanced wound care ... based on a,number of new products that are finding ... direct salespersons in the US a year ago, now,has ... increase is a significant one,for Derma Sciences, which has ...
... pre-adoption clinical evaluation of ... Recent case of vCJD now means that all the population is susceptible to ... the disease, - Increased concerns over "second wave" of vCJD in individuals with much ... longer incubation times - P-Capt(R) prion reduction filter still the only proven method ...
... 17, 2008 Scientific studies on climate change, energy ... more than 145 million processing hours on supercomputers at ... Innovative and Novel Computational Impact on Theory and Experiment ... industry, academia and government research facilities receive access to ...
Cached Biology Technology:Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008 2Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008 3ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 2ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 3ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 4ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies 5Oak Ridge leads DOE INCITE effort in 2008 2Oak Ridge leads DOE INCITE effort in 2008 3Oak Ridge leads DOE INCITE effort in 2008 4
(Date:3/19/2015)... , March 19, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces its ... a news clip that aired this week on ... . In a segment "The Next Great Thing", ... ,a new way to pay, and ,a really big breakthrough ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
(Date:3/12/2015)... , March 12, 2015 ... a standardized identity and access management (IAM) solution ... implementation schedule. With Beta System,s new IAM package, ... best practices gleaned from multiple IAM implementations across ... the software as well as any necessary services ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2
... allow women diagnosed with cancer the opportunity to have children ... researchers at the University of Michigan Comprehensive Cancer Center have ... cancer treatments, a woman can preserve the hope of one ... thawing them safely so they can lead to pregnancy is ...
... cause of death among children in developing regions of ... or international health organizations and charities, according to investigators ... of pediatric cancer is occurring as the number of ... the efforts of the World Health Organization and international ...
... critical inhibitory step that is a key component ... neutrophil production and destruction. The research, published in ... process for disposal of dying neutrophils is actively ... the processes that control neutrophil turnover may contribute ...
Cached Biology News:Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment 2Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment 3Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 2Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 3White Blood Cell 'Waste Disposal' System Plays Critical Regulatory Role 2
Apoptosis Detection Systems and Reagents...
...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Anti-Mouse Qa.m8, Ascites (Clone 5035-24.1) (mouse IgG3)...
Biology Products: